Patients with recent onset non-ischaemic cardiomyopathy have a variable clinical course with respect to recovery of left ventricular ejection fraction (LVEF). The aim of this study was to understand whether temporal changes in diastolic function (DF) are associated with clinical outcomes independent of LVEF recovery.
Introduction
Heart failure (HF) represents a growing problem worldwide and is related to significant increased morbidity and mortality. Recent onset non-ischaemic cardiomyopathy can be related to either myocarditis or an idiopathic process. These patients represent an interesting cohort with variable clinical courses and outcomes, which have been largely associated with recovery of left ventricular (LV) systolic function. 1, 2 Our group had previously demonstrated that medical therapy, such as beta-blockers, and/or regression of the disease process in these patients has resulted in LV ejection fraction (LVEF) and systolic recovery (≥10% LVEF units) at 6 months † Presented in part at the 2013 European Society of Cardiology Scientific Sessions.
in as much as 70% of patients. 2 We also had shown that despite high prevalence of LV dyssynchrony at baseline, improvements were seen at 6 months in a large majority of patients receiving conventional medical therapy and associated with improvements in LVEF. 3 On the other hand, diastolic dysfunction by the Doppler echocardiography is of important prognostic value and predictive of survival in HF patients with either chronically reduced 4, 5 or preserved LVEF. 4 In patients with preserved LVEF, diastolic function (DF) worsening was recently shown to be prognostically important for the development of HF 6 and increased mortality. 7 It remains unknown whether temporal changes in DF class can predict outcomes independent of LVEF recovery in these patients with recent onset nonischaemic cardiomyopathy. Accordingly, our objective was to test the hypothesis that DF is of independent and incremental prognostic value to the recovery of LVEF in these patients.
Materials and methods

Study population
The Intervention in Myocarditis and Acute Cardiomyopathy (IMAC)-2 was a prospective, multicentre national heart, lung and blood institute (NHLBI)-sponsored trial investigation of myocardial recovery in subjects with recent onset (i.e. acute) non-ischaemic dilated cardiomyopathy and myocarditis that enrolled subjects at 16 centres (see the Supplementary data online) from May 2002 through December 2008. 2 All subjects had a LVEF of ≤40% by transthoracic echocardiography (TTE) and HF symptoms onset of ,6 months in duration.
Informed consent was obtained from all subjects, and the protocol was approved by the institutional review boards of all participating centres. Patients were followed up for up to 48 months. All end points including all-cause death, heart transplantation, and HF hospitalizations were adjudicated by an independent events committee. Subjects underwent coronary angiography and/or non-invasive screening to exclude coronary artery disease and transthoracic echocardiogram to rule out significant valvular disease. We excluded patients with: (1) coronary artery disease, defined as a single coronary artery stenosis of a major epicardial vessel .50% or a previous history of myocardial infarction; (2) any known cause of cardiomyopathy (i.e. uncorrected thyroid disease, systemic lupus erythematosus, haemochromatosis, sarcoidosis, etc.) or a history of familial cardiomyopathy; (3) atrial fibrillation; (4) past or present alcoholism; (5) uncontrolled hypertension despite medical therapy; (6) significant valvular heart disease; (7) pericardial disease; and (8) follow-up TTE study with incomplete diastolic functional data. Patients with a clinical history or echocardiographic pattern of apical ballooning, consistent with takotsubo cardiomyopathy, were not included. 2 Right ventricular endomyocardial biopsy was not routinely performed, based on current practice guidelines. 8 
Echocardiography
All echocardiographic studies were performed at the time of diagnosis of acute onset cardiomyopathy and at 6-month follow-up (mean 7 + 3 months) using commercially available echocardiography systems: Vivid 7 (GE-Vingmed, Horten, Norway), Sonos 5500, 7500, or iE 33 (Philips, Andover, Massachusetts), ACUSON Sequoia (Siemens Medical Solutions, Mountain View, CA), or Aplio 80 or Aplio Artida (Toshiba Medical Systems, Tokyo, Japan). Gain settings were adjusted for routine clinical grayscale 2D imaging to optimize endocardial definition.
The LV volumes and LVEF were assessed by biplane Simpson's rule using manual tracing of digital images. LV systolic function recovery in recent onset non-ischaemic cardiomyopathy was a priori defined as absolute LVEF increase ≥10% at 6-month follow-up. 3 The pulsed-wave Doppler transmitral inflow velocities and tissue Doppler-derived mitral annular velocities were obtained from apical fourchamber views for assessment of DF at baseline and at 6-months followup in accordance with the European Association of Echocardiography/ American Society of Echocardiography guidelines 4 
Statistical analysis
Baseline demographic data and clinical variables were descriptively summarized with continuous variables expressed as mean + SD and categorical data presented as percentage frequency. Differences between the groups were compared with Student's t-test and analysis of variance for continuous variables and the x 2 test for categorical variables.
Univariate Cox proportional hazard analysis was performed to test for associations of the combined end point of death, heart transplantation, and HF hospitalization. Multivariate Cox proportional hazards modelling was used to risk-adjust comparisons for the combined end point. Variables were selected upon clinical relevance and chosen on the basis of events rate. Multivariate logistic regression analysis was obtained to identify the predictors of DF improvement at 6 months. Statistical analysis was performed using SPSS software (Version 21, SPSS, Inc., Chicago, IL), and P values ,0.05 were taken as significant.
Results
The study group consisted of 147 patients with complete data sets consisting of both baseline and 6-month follow-up assessment of systolic and DFs (Figure 1 ). Patients were classified into two groups according to the changes in diastolic functional class, as those with improvement in DF (n ¼ 85) and those in which DF remained unchanged or worsened at 6 months (n ¼ 62). Table 1 outlines the baseline demographics, clinical, and echocardiographic characteristics of both groups. In terms of baseline clinical characteristics and medical therapy, there were no significant differences noted between the two groups. This was a relatively young cohort with the mean age of 46 + 14 years and 40% were female, including 14 (10%) with peripartum cardiomyopathy. Fourteen (10%) subjects underwent an endomyocardial biopsy that revealed non-specific inflammation in 13 (9%) subjects and myocarditis in only one subject (1%). HF symptom onset was 2.3 + 1.7 months. Baseline LVEF was 23 + 8% (interquartile range: 16-30%).
At 6 months, LVEF improved to 41 + 12% (interquartile range: 31-52%), with 71% having LV systolic recovery (an absolute LVEF increase ≥10% ejection fraction units). DF improved in 58%, was unchanged in 28%, and worsened in 14%. Over a mean follow-up of 1.8 + 1.2 years, there were 18 events: 11 HF hospitalizations, 3 deaths, and 4 heart transplants.
Baseline echocardiographic parameters and diastolic function changes
Comparison of baseline echocardiographic parameters is shown in Table 1 . Patients with worse baseline echocardiographic findings (i.e. larger baseline LV end-diastolic volume index, but not LV enddiastolic diameter, lower LVEF, and worse DF) demonstrated DF improvement at 6-month follow-up. Specifically, the patients with DF improvement had worse baseline diastolic mitral inflow (E/A) ratio, shorter deceleration time, and higher LV filling pressures (E/e' ratio).
Interval changes in diastolic function class
Comparison of diastolic functional class changes over 6-month follow-up period is shown in Tables 2 and 3. As a whole, DF improved in 58%, remained unchanged in 28%, and worsened in 14% of the cohort. The major interval change was significant decrease in the prevalence of Stage 3 diastolic dysfunction (restrictive filling pattern) at the 6-month follow-up with the majority of these patients improving ≥2 diastolic functional classes to either normal DF or to mild diastolic dysfunction (Stage 1). In addition, nearly 40% of patients had complete normalization of their DF at follow-up.
Diastolic function class changes and outcomes
Univariate Cox regression analysis was performed to determine the predictors of the combined end point (HF hospitalization, heart transplant, and all-cause mortality) ( Table 4) . There was no association between race (non-black vs. black) and clinical outcomes. None of the baseline clinical and/or echocardiographic characteristics were associated with the combined end point, except for diastolic blood pressure. In contrast, the 6-month follow-up TTE study was very informative with several echocardiographic variables significantly associated with worse outcomes such as higher LV enddiastolic and end-systolic volume index, persistency of baseline diastolic dysfunction (i.e. DF class ≥Stage 1) and higher LV filling pressures expressed by elevated mean E/e'. On the other hand, LVEF and DF improvements at 6 months were associated with decreased likelihood for the combined end point ( Table 4) . Of note, in the original IMAC-2 trial 2 (n ¼ 373), larger baseline left ventricular end-diastolic diameter (LVEDD) was associated with higher event rate and lower chance of LV systolic recovery. However, in this subgroup analysis (n ¼ 147), baseline LVEDD was not predictive of the combined end point (HR ¼ 1.24, 95% CI 0.70 -2.21, P ¼ 0.46), which could be the result of a smaller sample size and type II error.
In other to avoid model overfitting, multivariate Cox regression analysis was performed including only two variables selected upon clinical relevance and chosen on the basis of events rate. Since LV systole and diastole are closely linked to each other, adjustment for parameters that would measure LVEF at 6-month follow-up would be necessary. The models with the most significant associations are shown in Table 5 . Both models demonstrate the Diastolic function improvement in patients with acute non-ischaemic cardiomyopathy independent prognostic value of DF class improvement at 6 months, over LVEF or LV systolic function recovery (increase in LVEF of ≥10% at 6 months). Figure 2 shows the adjusted Cox proportional hazard curves comparing patients with improved DF vs. those with unchanged or worsened DF at 6-month follow-up. Patients with diastolic functional class improvement over 6-month follow-up had higher freedom from HF hospitalization, death, or heart transplant even after adjustment for the 6-month follow-up LVEF ( Table 5 , Model 1). Diastolic functional class improvement at 6 months also had incremental prognostic value when added to 6-month follow-up LVEF (X 2 changed from 12.6 to 18, P ¼ 0.02). A subgroup analysis of patients with LV systolic function recovery (absolute increase in LVEF of ≥10% at 6 months, n ¼ 105) showed that DF improvement was particularly important for these patients (HR ¼ 0.06, 95% CI 0.007 -0.46, P ¼ 0.008) ( Figure 3) . Specifically, patients with interval improvements in both LVEF and DF had a lower likelihood of the combined end point. The impact of DF improvement in patients without LVEF improvement at 6 months (n ¼ 42) was not statistically significant (HR ¼ 0.71, 95% CI 0.14-3.64, P ¼ 0.68), although we were underpowered to assess these differences.
Predictors of diastolic function class improvement
Multivariate logistic regression analysis was performed to identify the predictors of DF class improvement at 6 months. Variables were chosen on the basis of events rate and upon clinical relevance. and aldosterone blockers at baseline. From echocardiographic characteristics, an improvement of LV remodelling translated as a greater reduction of LV end-systolic volume index (baseline minus 6-month follow-up), as well as worse baseline DF parameters such as shorter deceleration time and increased mean LV filling pressures were associated with DF improvement at 6 months in this cohort (Table 6 ). Similar results were obtained when using Delta LV end-diastolic volume index instead of Delta LV end-systolic volume index (see Supplementary data online, Table S1 ).
We also evaluated whether changes in LV relaxation (Delta e') and filling pressures (Delta E/e') were associated with temporal Tables S2 and S3) .
Discussion
This multicentre prospective study, performed on a large series of recent onset non-ischaemic cardiomyopathy patients with baseline and follow-up data, has several important findings. First, diastolic dysfunction is prevalent among these patients and dynamic, with improvements seen in up to 58% of the cohort at 6-month follow-up. Second, patients presenting with worse baseline echocardiographic parameters had the greatest improvement in their DF class. Our third and most important finding is that DF recovery is associated with favourable outcomes, providing independent and incremental prognostic value to 6-month follow-up LVEF in these patients with recent onset non-ischaemic cardiomyopathy. Taken together, these findings suggest that diastolic functional recovery is as prognostically important as LVEF recovery, independent of follow-up LVEF and/or LV systolic recovery, indicating a potential therapeutic target for these patients.
Recent onset non-ischaemic cardiomyopathy is an interesting cohort of patients presenting with either myocarditis or an idiopathic process leading to HF symptoms. The clinical course and outcomes of these patients are variable and historically linked to the recovery of LV systolic function. Diastolic function improvement in patients with acute non-ischaemic cardiomyopathy these patients demonstrate LV systolic recovery (≥10% LVEF units) in 6 months. 2 However, a subset of these patients still have poor outcomes (HF hospitalization, death, heart transplantation), which are not entirely explained by their LVEF recovery. The clinical significance of DF changes in the setting of recent onset nonischaemic cardiomyopathy has not been studied. The majority of studies looking at the prognostic value of DF assessment in patients with HF with either reduced or preserved LVEF have used the approach of a single time-point assessment. 4 The worst prognosis has been seen in patients with either moderate (pseudonormal filling, Stage 2) or severe (restrictive filling pattern, Stage 3 diastolic dysfunction) in several groups of patients with either ischaemic or non-ischaemic cardiomyopathy. 4,5,9 -11 In this substudy from IMAC-2 trial, diastolic dysfunction was prevalent (up to 80% of the cohort at baseline), albeit dynamic with improvements seen in up to 58% of the cohort at 6-month followup. Diastolic functional improvement was associated with the use of diuretics and aldosterone blockade agents producing improvement in LV filling pressures and remodelling. Importantly, diastolic functional improvement was as prognostically important as LVEF recovery for these patients, and provided incremental prognostic value to the risk stratification. This study also confirms the prognostic importance of non-invasive estimation of LV filling pressures at followup using the E/e' ratio (HR ¼ 1.12, 95% CI 1.07-1.18, P , 0.0001, Table 4 ), which has been previously shown to be an independent prognostic factor for mortality and readmission for HF 12 adding incremental value to other Doppler parameters of DF, 13 B-type natriuretic peptide 14 and LVEF. 15 Recently, Cavalcante et al. evaluated the prognostic value of diastolic functional assessment over cardiac magnetic resonance data including myocardial scar burden, peri-infarct zone, and LV remodelling characteristics in patients with advanced ischaemic cardiomyopathy. The authors demonstrated that diastolic functional assessment provides incremental prognostic value to the baseline clinical characteristics and cardiac magnetic resonance data including myocardial scar burden and peri-infarct zone. DF classification improved risk stratification, in particular for those patients with significant myocardial scar burden. 5 The importance of temporal changes seen with DF has been studied in the group of patients with preserved LVEF. Kane et al. identified, in a large population cohort study of individuals with preserved LV systolic function, that persistency and/or interval worsening of DF was associated with an increased risk for the development of HF syndrome. Over a mean follow-up time of 6.3 + 2.3 years, cumulative HF incidence was 2.6% for patients whose DF remained normal or normalized, 7.8% for patients who had persistent or progression to mild, and 12.2% for patients with persistent or progression to moderate/severe diastolic dysfunction. 6 Aljaroudi et al. have
shown, in a cohort of outpatients with preserved LV systolic function, that worsening of DF over a mean follow-up of 1.6 + 0.8 years is as prognostically important as interval decrease in LVEF to ,55% to predict all-cause mortality. 7 Another single-centre study by LV systolic function recovery was a priori defined as an absolute increase in LVEF ≥10% at 6-month follow-up. Figure 2 Adjusted Cox proportional hazard curves comparing patients with improved DF vs. those with unchanged or worsened DF at 6-month follow-up. Patients with DF class improvement at 6-month follow-up had higher freedom from HF hospitalization, death, or heart transplant even after adjustment for the 6-month LVEF at follow-up.
dysfunction and did not use tissue Doppler imaging to assess diastolic functional changes. 16 However, the importance of temporal changes in DF for patients with HF and depressed systolic function has not been well studied. 19 However, in all three studies, DF was assessed only using pulsed-wave Doppler measurements, which is preload dependent, and not in keeping with current societal guidelines, which require assessment using tissue Doppler velocity imaging. 4 Our findings suggest that both systolic and DFs have a dynamic component in recent onset non-ischaemic cardiomyopathy. DF improvement can be also seen in a significant number of patients with recent onset non-ischaemic cardiomyopathy, with 40% of the cohort demonstrating normalization of DF, a finding previously reported in patients with preserved LV systolic function. 6, 7 Interval improvement of DF is particularly important for patients with LVEF improvement at 6 months, as those patients with LV systolic recovery but with unchanged or worsened diastolic functional class have a 25% event rate at 18 months of follow-up ( Figure 3) . In addition, our findings suggest that worse baseline echocardiographic parameters were not predictive of worse outcomes, but rather associated with DF improvement at 6-month follow-up. Diastolic functional improvement was associated with the use of diuretics and aldosterone blockade agents which produced improvement in LV filling pressures and remodelling. Although the observed DF improvement could be in part related to modified preload conditions, the favourable reverse remodelling suggests a potential improvement in myocardial mechanics and LV dyssynchrony in these patients as recently demonstrated by our group. 3 Taken together, our findings suggest a continued follow-up imaging for these patients for both prognostication and risk stratification since the 6-month follow-up echocardiogram can identify important modifiable variables such as increased LV filling pressures (mean E/e' ratio), which has been properly validated against invasive haemodynamics in a variety of patients and clinical scenarios. 4, 20, 21 Study limitations Patients with LVEF increase ≥10% and DF class improvements at 6-month follow-up had higher freedom from HF hospitalization, death, or heart transplant when compared with those with LVEF improvement but with unchanged and/or worsened DF.
for event adjudication. An important limitation was that routine Doppler and tissue Doppler data used to classify DF were not part of the original echocardiographic protocol and therefore not available on all consecutive IMAC-2 patients either at baseline and/or at follow-up. Nonetheless, this subgroup analysis was capable of providing important clinical observations. Another limitation was that both mitral inflow velocities and tissue Doppler of the mitral annulus are not completely load independent and may be influenced by differences in loading conditions. 22 However, these non-invasive indices have been widely used to estimate LV DF and recommended by the societal guidelines 4 as they have been well validated and importantly associated with patient outcomes, although potentially less accurate in acute decompensated patients with advanced systolic HF. 23 Left atrial volume index and performance of Valsalva manoeuvre during mitral inflow Doppler acquisition were not available for analysis, both of which could have added further insights into the chronicity and severity of diastolic dysfunction. 4 It would be of interest to incorporate data on pulmonary vein Doppler and pulmonary artery systolic pressure, which were not routinely obtained. Follow-up LVEF and Doppler data for DF were re-evaluated only at the 6-month follow-up period as pre-specified in the study protocol. This is appropriate time frame to assess the changes of both systolic and diastolic functions in HF patients treated with chronic oral therapy. Risk adjustment was limited by the event rate at a mean follow-up of 48 months, constraining the number of variables in the multivariate model. Although HF hospitalizations were more common, nearly 40% of the events were related to either death or heart transplantation adjudicated by an independent events committee. DF, although was assessed at two time points, was only measured at rest. It is possible that dynamic changes brought by exercise (i.e. supine bicycle or treadmill) could have been also helpful in the risk stratification and management of these patients. Lastly, LVEF represents only one of the components of LV systolic performance. Information regarding global longitudinal strain (GLS) could have provided additional prognostic information for these patients, but was not part of the original study design that was based on biplane LVEF as the standard measure of LV systolic function. It is possible that changes in GLS may be additive to those seen with LVEF. A study protocol testing the incremental prognostic value of GLS in this special cohort of patients would be of great interest for a future study.
Conclusions
In patients presenting with recent onset non-ischaemic cardiomyopathy, significant improvements in both LVEF and DF can be seen within 6 months. Since the clinical course is variable, markers of adverse outcome for clinical management and risk stratification are important to be identified. We have found that diastolic functional improvement was associated with the use of diuretics and aldosterone blockade agents producing improvement in LV filling pressures and remodelling. Diastolic functional recovery appears to be as prognostically important as LV systolic recovery for these patients, adding incremental prognostic value to the risk stratification and potentially a future therapeutic target. Our results need to be verified and confirmed by other larger cohorts to obtain external validity. It might be important to follow longitudinally both systolic and diastolic functions in these patients, given that their clinical outcomes cannot be entirely explained by the LVEF improvement, which commonly occurs.
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